Zymeworks Announces Expiration of Hart-Scott-Rodino Waiting Period for Zanidatamab License Agreement with Jazz PharmaceuticalsBusiness Wire • 11/29/22
Wall Street Analysts Believe Zymeworks Inc. (ZYME) Could Rally 59%: Here's is How to TradeZacks Investment Research • 11/22/22
Zymeworks Inc. (ZYME) Just Flashed Golden Cross Signal: Do You Buy?Zacks Investment Research • 11/21/22
Zymeworks Announces Abstract For Zanidatamab In Late-Line HER2-Positive Hormone-Receptor Positive (HR+) Metastatic Breast Cancer At The San Antonio Breast Cancer Symposium (SABCS)Business Wire • 11/21/22
Zymeworks Provides Corporate Update and Reports Third Quarter 2022 Financial ResultsBusiness Wire • 11/08/22
Zymeworks: A Binary Event With BTC Data By End-2022 Which May Trigger MilestoneSeeking Alpha • 10/26/22
Zymeworks Inc. (ZYME) Surges 15.9%: Is This an Indication of Further Gains?Zacks Investment Research • 10/20/22
Zymeworks Early R&D Day Highlights Progress in Development of Novel Pipeline Assets and Applications of Proprietary Next-Generation Technology PlatformsBusiness Wire • 10/20/22
Zymeworks To Host Conference Call on Exclusive Licensing Agreement of ZanidatamabBusiness Wire • 10/19/22
Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific AntibodyPRNewsWire • 10/19/22